Breadcrumb

Martha A. Zeiger, M.D.

Martha A. Zeiger, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Surgical Oncology Program

RESEARCH SUMMARY

Martha A. Zeiger, M.D. is an internationally renowned endocrine surgeon and scientist who has been a leader in developing molecular diagnostics for thyroid cancer. In addition to her role as Adjunct Investigator in the Surgical Oncology Program, Dr. Zeiger also directs CCR's Office of Surgeon-Scientist Career Development, Office of the Clinical Director. As Director, she leads a team studying and designing future pathways for the professional development of surgeon-scientists. Dr. Zeiger's research interests focus on TERT gene expression regulation, molecular marker diagnostic panel development and molecular biological aspects of thyroid cancer development. 

Areas of Expertise

Regulation Of TERT Gene Expression
Molecular Marker Panels For Diagnosis And Prognosis Of Thyroid Cancer
Professional Development Of Future Surgeon-scientists
Adrenal Tumors
Medullary Thyroid Cancer
Hyperparathyroidism

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them. 

Publications

Selected Key Publications

Characterization of Human Telomerase Reverse Transcriptase Promoter Methylation and Transcription Factor Binding in Differentiated Thyroid Cancer Cell Lines

Avin BA, Wang Y, Gilpatrick T, Workman RE, Lee I, Timp W, Umbricht CB, Zeiger MA.
Genes Chromosomes & Cancer. 58(8): 530-540, 2019. [ Journal Article ]

Integrated Genomic Characterization of Papillary Thyroid Carcinoma

Cancer Genome Atlas Research Network
Cell. 159(3): 676-690, 2014. [ Journal Article ]

Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology

Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR.
New England Journal of Medicine. 367(8): 705-715, 2012. [ Journal Article ]

Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers

Han PA, Kim HS, Cho S, Fazeli R, Najafian A, Khawaja H, McAlexander M, Dy B, Sorensen M, Aronova A, Sebo TJ, Giordano TJ, Fahey TJ 3rd, Thompson GB, Gauger PG, Somervell H, Bishop JA, Eshleman JR, Schneider EB, Witwer KW, Umbricht CB, Zeiger MA.
Thyroid. 26(4): 532-542, 2016. [ Journal Article ]

RAS Mutations, and RET/PTC and PAX8/PPAR-gamma Chromosomal Rearrangements Are Also Prevalent in Benign Thyroid Lesions? Implications Thereof and A Systematic Review

Najafian A, Noureldine S, Azar F, Atallah C, Trinh G, Schneider EB, Tufano RP, Zeiger MA.
Thyroid. 27(1): 39-48, 2017. [ Journal Article ]

Team

Research Analyst
Lindsay Demblowski